BERKELEY, Calif., Dec. 10, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, reported results demonstrating the advantages of its monoclonal antibody technologies in the rapid development of a first-in-class multiple antibody product candidate, XOMA 3AB. XOMA 3AB is designed to neutralize botulinum neurotoxin Type A, which causes paralysis and is a bioterror threat. The results were presented at the 20th Annual International Conference on Antibody Engineering being held December 6 to 10 in San Diego, CA.
